Compare Quest Diagnostics Inc (DGX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Wayfair Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Wayfair Inc trades at $105.86 (market cap $14.40B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Wayfair Inc for 8 Days on average.
| DGX | W | |
|---|---|---|
Market Cap | $25.48B | $14.40B |
Volume | 941,866 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $119.05 |
52-Week Low | $173.49 | $57.40 |
Typical Hold Time | 56 Days | 8 Days |
Enterprise Value | $31.23B | $16.73B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Wayfair (W) trades at $105.89, up 1.36% with bullish technical signals from moving averages. The company shows revenue growth to $12.9B in 2026 but maintains negative net margins around -2.5%. Recent Q2 2026 earnings beat expectations at $0.95 EPS versus $0.904, while Q3 2026 results are pending. Analyst sentiment is positive with 54% buy ratings and a $114.13 consensus target. The stock faces headwinds from high debt-to-asset ratio of 95.11% and persistent unprofitability despite top-line expansion.
Wayfair presents a mixed outlook with strong revenue growth and technical momentum offset by profitability challenges. The primary opportunity lies in continued market share gains and operational efficiency improvements. Key risks include competitive pressures in e-commerce, high leverage, and macroeconomic sensitivity. Investors should weigh the bullish analyst consensus against fundamental weaknesses in margin performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
